AstraZeneca will move to seek regulatory approval of its antibody cocktail after a study showed the drug significantly reduced the risk of developing symptomatic Covid-19.
That would make it the first long-acting drug that is not a vaccine that has demonstrated prevention of the disease in a clinical trial.
The Anglo-Swedish drugmaker said on Friday that its AZD7442 antibody combination showed a 77 per cent reduction in the development of symptomatic Covid compared with placebo. There were no severe Covid cases or deaths in those treated with the drug, while the placebo arm accrued three cases of severe disease, including two deaths.
您已阅读23%（639字），剩余77%（2116字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。